SCHEMBL26098698

SCHEMBL26098698

COc1ccc(OC)c(CCNCc2cc(C)cc([N+](=O)[O-])c2)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.54
MAPT P10636 3/20 0.53
ALDH1A1 P00352 2/20 0.53
HTT P42858 1/20 0.53
HTR2C P28335 3/20 0.51
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
CDC25C P30307 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA9 Q16790 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24733557 0.81 HTR2A (0.61) HTR2AHTR2C
SCHEMBL30277338 0.81 HTR2A (0.55) HTR2AMAPTHTR2CMEN1KMT2A
SCHEMBL31188806 0.81 HTR2A (0.61) HTR2AHTR2C
SCHEMBL24733560 0.81 HTR2A (0.55) HTR2AALDH1A1HTR2C
SCHEMBL24733587 0.81 HTR2A (0.55) HTR2AMAPTHTR2CMEN1KMT2A
SCHEMBL24733377 0.81 HTR2A (0.55) HTR2AHTR2C
SCHEMBL18177863 0.81 CDC25C (0.64) HTR2AMAPTALDH1A1HTTHTR2C
Hydrochloric Acid SCHEMBL26097571 0.81 HTR2A (0.54) HTR2AHTR2C
SCHEMBL24734847 0.79 HTR2A (0.55) HTR2AHTR2C
SCHEMBL24733403 0.76 HTR2A (0.60) HTR2AMAPTALDH1A1HTR2CMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282712-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS ATAI THERAPEUTICS INC (US) 2025-09-11 US disclosed
US-20250268846-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS ATAI THERAPEUTICS INC (US) 2025-08-28 US disclosed
US-12351537-B2 Dimethoxyphenylalkylamine activators of serotonin receptors ATAI THERAPEUTICS, INC. (US) 2025-07-08 US disclosed
US-12343319-B2 Compositions and methods for treatment of diseases and disorders ATAI THERAPEUTICS, INC. (US) 2025-07-01 US disclosed
US-20240366531-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS Atai Therapeutics Inc. 2024-11-07 US disclosed
US-20240294461-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS Atai Therapeutics Inc. 2024-09-05 US disclosed
US-11926574-B2 Dimethoxyphenylalkylamine activators of serotonin receptors Atai Therapeutics Inc. (US) 2024-03-12 US disclosed
CN-117500487-A Dimethoxy phenyl alkylamine activators of serotonin receptors 恩泰奥吉尼克斯生物科学公司 2024-02-02 CN disclosed
US-20230138118-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS Atai Therapeutics Inc. 2023-05-04 US disclosed
US-20230138118-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS Atai Therapeutics Inc. 2023-05-04 US disclosed
US-20230138118-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS Atai Therapeutics Inc. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12343319-B2 Compositions and methods for treatment of diseases and disorders HCRTR1, H1-10, RAB10 HTR2A 480/4885MAPT 938/4885ALDH1A1 1665/4885
US-11926574-B2 Dimethoxyphenylalkylamine activators of serotonin receptors HTR1A, HTR7, HTR4 HTR2A 12/4885MAPT 2246/4885ALDH1A1 1077/4885
US-20230138118-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS HTR1A, HTR7, HTR4 HTR2A 12/4885MAPT 2246/4885ALDH1A1 1077/4885
US-12351537-B2 Dimethoxyphenylalkylamine activators of serotonin receptors HTR1A, HTR7, HTR4 HTR2A 12/4885MAPT 2246/4885ALDH1A1 1077/4885
US-20250268846-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS HCRTR1, RAB10, H1-10 HTR2A 480/4885MAPT 937/4885ALDH1A1 1750/4885
US-20250282712-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS HTR1A, HTR7, HTR4 HTR2A 12/4885MAPT 2246/4885ALDH1A1 1077/4885
US-20240294461-A1 DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS HTR1A, HTR7, HTR4 HTR2A 12/4885MAPT 2246/4885ALDH1A1 1077/4885
US-20240366531-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS HCRTR1, H1-10, RAB10 HTR2A 480/4885MAPT 938/4885ALDH1A1 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.